<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916458</url>
  </required_header>
  <id_info>
    <org_study_id>A6181227</org_study_id>
    <secondary_id>ATILA</secondary_id>
    <nct_id>NCT03916458</nct_id>
  </id_info>
  <brief_title>REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA</brief_title>
  <acronym>ATILA</acronym>
  <official_title>REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (ATILA STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational, retrospective, multicentre study in spanish patients with metastatic Renal
      Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with
      previous cytokine therapy is accepted) according to clinical practice who obtained a complete
      response (CR) to treatment in one of these 2 situations:

        1. Complete response (CR) obtained exclusively with first-line sunitinib treatment
           (sunitinib CR).

        2. Response obtained after a period of time on treatment with sunitinib in which local
           treatment was also performed (surgery of the residual metastasis/metastases,
           radiofrequency ablation or radiotherapy) to achieve the total macroscopic disappearance
           of the disease, according to the opinion of the physician responsible for the patient
           (CR + local treatment).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients in good, intermediate and poor prognosis who achieve complete response in the investigator´s opiniion or at least 2 consecutive CT scans</measure>
    <time_frame>Between 2007 and 30 september 2018</time_frame>
    <description>Associations between complete response from a clinical point of view and the baseline characteristics of both the patient and the tumour</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients who achieve a complete response with previous nephrectomy</measure>
    <time_frame>Between 2007 and 30 September 2018</time_frame>
    <description>Association between complete response and nephrectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients who achieve a complete response with clear cell histology, cromophobe, papilar I and II, and clear cell with sarcomatoid characteristics (%)</measure>
    <time_frame>Between 2007 and 30 September 2018</time_frame>
    <description>Association between complete response to sunitinib and tumour histology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The median time on treatment with sunitinib until lesion complete remission is reached</measure>
    <time_frame>From treatment initiation to complete remission(Between 2007 and 30 September 2018)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The median duration of complete response (CR)</measure>
    <time_frame>Disease relapse to disease progression (from 3 month on treatment to 11 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free Survival</measure>
    <time_frame>Baseline up to recurrence or death (from 9 months until progression or 11 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration and dose/schedule distribution</measure>
    <time_frame>From treatment initiation to 30 September 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who received local treatment</measure>
    <time_frame>From 2007 to 30 September 2018</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of adverse events of discontinuation due to sunitinib toxicity</measure>
    <time_frame>From treatment initiation to complete remission(Between 2007 and 30 September 2018)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of toxicity to sunitinib in higher grade</measure>
    <time_frame>From treatment initiation to 30 September 2018</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Subjects with reported metastatic renal cell carcinoma</arm_group_label>
    <description>The subjects have been treatment with sunitinib and they reached complete remission</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population eligible for this study includes any patient with advanced or
        metastatic renal cell cancer who has been treated with Sunitinib and has achieved CR of the
        tumour and its metastases at any time during treatment and according to the usual
        assessment criteria in daily clinical practice, whether it was obtained with sunitinib
        alone or if a local treatment was needed to eradicate all the lesions: (surgery of the
        residual metastases, radiofrequency ablation or radiotherapy)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are 18 year-old or over who have been treated for metastatic renal cell
             carcinoma with sunitinib as first-line treatment (treatment with prior cytokine
             therapy is accepted) between 2007 and 30 September 2018 and who have obtained as a
             best treatment response the total remission of the disease in the opinion of the
             doctor in charge from a clinical, radiological and/or macroscopic point of view. This
             response must have been reached through two possible strategies:

             A) Systemic treatment with sunitinib alone. B) Treatment with sunitinib and subsequent
             local treatment for one or more residual lesions that have not responded to the drug
             (traditional surgery, radiotherapy, SBRT (Stereotactic Body Radiation Therapy)).

          2. The duration of CR must have been confirmed with at least 2 consecutive imaging tests,
             without having a limit in the duration of this response. Although the patient had
             progressed subsequently, he/she may be included in this registry.

          3. Patients from any risk group

          4. Tumours of any histology

        Exclusion Criteria:

          1. Patients treated with another drug other than Sunitinib.

          2. Patients with no radiology reports proving CR.

          3. Patients with no record of the dose and regimen received with Sunitinib.

          4. Patients who achieved complete remission after 30 September 2018.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario la Mancha Centro</name>
      <address>
        <city>Alcázar de San Juan</city>
        <state>Ciudad REAL</state>
        <zip>13600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital universitario Donostia</name>
      <address>
        <city>Donostia</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Parla</city>
        <state>Madrid</state>
        <zip>28981</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospita Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <state>Madrid</state>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Elena</name>
      <address>
        <city>Valdemoro</city>
        <state>Madrid</state>
        <zip>28342</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ferrol</name>
      <address>
        <city>A Coruña</city>
        <zip>15011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de León</name>
      <address>
        <city>León</city>
        <zip>24080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti / Servicio de Oncología Médica</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial de Segovia</name>
      <address>
        <city>Segovia</city>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Peset</name>
      <address>
        <city>València</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A6181227</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Renal Cell</keyword>
  <keyword>Disease-Free Survival</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Protein Kinase Inhibitors</keyword>
  <keyword>Angiogenesis Inhibitors</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

